[Immunomodulatory effects of intravenous immunoglobulins].

Abstract

Intravenous immunoglobulin (IVIg) has been used for many years in the treatment of primary and secondary antibody deficiencies. IVIg was first demonstrated to be effective in auto-immune desorders twenty years ago in the treatment of idiopathic thrombocytopenic purpura. The beneficial effect of IVIg has since been established in the Guillain-Barré syndrome, chronic inflammatory demenilating polyneuropathy, myasthenia gravis, dermatomyositis, Kawasaki syndrome and graft versus host disease. The beneficial effect of IVIg has been suggested in a large number of other auto-immune and systemic inflammatory conditions. The mode of action of IVIg is complex, involving Fc receptor blockade, interference with complement activation and the cytokine network, provision of anti-idiotypic antibodies and modulation of T and B cell activation and differentiation. Such a broad range of activities reflects the function of normal circulating immunoglobulins in maintaining tolerance to self in healthy individuals.

• Authors: M Kazatchkine, L Mouthon, S V Kaveri
• Journal: Annales de medecine interne (Ann Med Interne (Paris)) Vol. 151 Suppl 1 Pg. 1S13-8 (May 2000) ISSN: 0003-410X [Print] France
• Vernacular Title: Effets immunomodulateurs des immunoglobulines intraveineuses.
• PMID: 10896983 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Adjuvants, Immunologic
• Antibodies, Anti-Idiotypic
• Cytokines
• Immunoglobulins, Intravenous
• Receptors, Fc

Topics

• Adjuvants, Immunologic (therapeutic use)
• Antibodies, Anti-Idiotypic (therapeutic use)
• Autoimmune Diseases (therapy)
• Complement Activation (immunology)
• Cytokines (immunology)
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Deficiency Syndromes (therapy)
• Lymphocyte Activation (immunology)
• Polyneuropathies (therapy)
• Receptors, Fc (antagonists & inhibitors)